ClinicalTrials.gov
ClinicalTrials.gov Menu

Time To Efficacy and Onset Of Action Of Linezolid

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00147511
Recruitment Status : Completed
First Posted : September 7, 2005
Last Update Posted : May 10, 2011
Sponsor:
Information provided by:
Pfizer

Brief Summary:
To assess the onset of action of linezolid

Condition or disease Intervention/treatment Phase
Gram-Positive Bacterial Infections Skin and Connective Tissue Diseases Drug: linezolid Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 118 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections
Study Start Date : June 2003
Actual Study Completion Date : June 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Linezolid




Primary Outcome Measures :
  1. Time to defervescence

Secondary Outcome Measures :
  1. Reduction of CRP levels Reduction of leucocyte count


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • suspected grampositive infection
  • fever > 38 C

Exclusion Criteria:

  • Infections to be treated successfully by surgical procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00147511


Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer
ClinicalTrials.gov Identifier: NCT00147511     History of Changes
Other Study ID Numbers: OXAA-0026-162
First Posted: September 7, 2005    Key Record Dates
Last Update Posted: May 10, 2011
Last Verified: May 2011

Additional relevant MeSH terms:
Infection
Bacterial Infections
Connective Tissue Diseases
Gram-Positive Bacterial Infections
Linezolid
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action